The SARS-CoV-2 infection has affected millions of lives across the globe, with a vulnerable population like cancer patients being more susceptible to it. Therefore, there is an urgent need for safe and efficient vaccines to protect such a population. However, since the patients with malignancies have been excluded from the study trials, the available data on this patient population is scarce.
Recently, it has been demonstrated that the approved mRNA-based vaccines exhibit a promising potential to manage COVID-infected cancer patients. Recent studies have demonstrated that cancer patients have few antibody responses to vaccination compared to the immunocompetent controls. The objective of this 140-day study conducted by researchers at Stanford was to generate data to estimate the effectiveness of SARS-CoV-2 vaccination in cancer patients in a real-world setting following the vaccine…
